Alfred Müller
Research Subjects
Alfred Müller has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Steffen Wahler
St. Bernward GmbH, Hamburg, Germany
2 shared publications - Anke Dauch
Department of Cardiology, Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany
1 shared publication - Henrik Schneider
Department of Cardiology, Heart Center Rostock, Medizinische Klinik I, Universitätsklinikum Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany
1 shared publication Hueseyin Ince
Heart Center Rostock, Universitätsklinikum Rostock, Ernst-Heydemann-Str. 6, 18057, Rostock, Germany
1 shared publication- Manfred Beck
Universitätsklinikum Tübingen, Tübingen, Germany
1 shared publication - Peter Kurzweil
Ostbayerische Technische Hochschule Amberg-Weiden, 92224 Amberg, Germany
1 shared publication
Latest Publications
- Open Access
- 12 July 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (14) , 7425
The Ecological Footprint of COVID-19 mRNA Vaccines: Estimating Greenhouse Gas Emissions in Germany
Compared to the medical, economic and social implications of COVID-19 vaccinations, little attention has been paid to the ecological balance to date. This study is an attempt to estimate the environmental impact of two mRNA vaccines in terms of CO2 equivalents with respect to their different freezing strategies and supply chain organization. Although it is impossible to accurately calculate the actual environmental impact of the new biochemical synthesis technology, it becomes apparent that transport accounts for up to 99% of the total carbon footprint. The emissions for air freight, road transportation and last-mile delivery are nearly as 19 times the emissions generated from ultra-deep freeze technologies, the production of dry ice, glass and medical polymers for packaging. The carbon footprint of a single mRNA vaccine dose injected into a patient is about 0.01 to 0.2 kg CO2 equivalents, depending on the cooling technology and the logistic routes to the vaccination sites in Germany.
- 12 July 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (14) , 7425
Open AccessThe Ecological Footprint of COVID-19 mRNA Vaccines: Estimating Greenhouse Gas Emissions in Germany
Compared to the medical, economic and social implications of COVID-19 vaccinations, little attention has been paid to the ecological balance to date. This study is an attempt to estimate the environmental impact of two mRNA vaccines in terms of CO2 equivalents with respect to their different freezing strategies and supply chain organization. Although it is impossible to accurately calculate the actual environmental impact of the new biochemical synthesis technology, it becomes apparent that transport accounts for up to 99% of the total carbon footprint. The emissions for air freight, road transportation and last-mile delivery are nearly as 19 times the emissions generated from ultra-deep freeze technologies, the production of dry ice, glass and medical polymers for packaging. The carbon footprint of a single mRNA vaccine dose injected into a patient is about 0.01 to 0.2 kg CO2 equivalents, depending on the cooling technology and the logistic routes to the vaccination sites in Germany.
- Open Access
- 8 April 2013
- Published by Springer Nature in Health Economics Review
- Vol. 3 (1) , 10
Short term cost effectiveness of a regional myocardial infarction network
Myocardial infarction networks have been shown to improve guideline adherent therapy and outcomes in patients presenting with acute ST-elevation myocardial infarction (STEMI). Our objective was to assess the short term cost effectiveness of a network structure. Outcome data and reimbursement data for the index hospital stay were gathered in consecutive patients with acute STEMI (n = 536) admitted to any of the hospitals in a 350.000 inhabitant rural network area during the years 2002 (n = 185), 2005 (n = 163) and 2008 (n = 188). Network structure was established between 2002 and 2005 aiming for identical treatment of all acute STEMI patients during 24 h/7d a week with primary angioplasty. Patient baseline characteristics in the different years were quite comparable. From 2002 to 2005 regional hospital mortality in STEMI patients decreased from 16% to 9%. Lower mortality under network conditions was confirmed in 2008. Reimbursement data of different years were standardized to exclude effects not induced by the network. The mean initial costs per saved live during the index stay were €7727 with a 95%-confidence interval of €-3.500 to €36.700 (referenced to the German reimbursement in 2005). The short term cost effectiveness of a myocardial infarction network organisation is within well accepted boundaries under conditions of the German reimbursement system.
- 8 April 2013
- Published by Springer Nature in Health Economics Review
- Vol. 3 (1) , 10
Open AccessShort term cost effectiveness of a regional myocardial infarction network
Myocardial infarction networks have been shown to improve guideline adherent therapy and outcomes in patients presenting with acute ST-elevation myocardial infarction (STEMI). Our objective was to assess the short term cost effectiveness of a network structure. Outcome data and reimbursement data for the index hospital stay were gathered in consecutive patients with acute STEMI (n = 536) admitted to any of the hospitals in a 350.000 inhabitant rural network area during the years 2002 (n = 185), 2005 (n = 163) and 2008 (n = 188). Network structure was established between 2002 and 2005 aiming for identical treatment of all acute STEMI patients during 24 h/7d a week with primary angioplasty. Patient baseline characteristics in the different years were quite comparable. From 2002 to 2005 regional hospital mortality in STEMI patients decreased from 16% to 9%. Lower mortality under network conditions was confirmed in 2008. Reimbursement data of different years were standardized to exclude effects not induced by the network. The mean initial costs per saved live during the index stay were €7727 with a 95%-confidence interval of €-3.500 to €36.700 (referenced to the German reimbursement in 2005). The short term cost effectiveness of a myocardial infarction network organisation is within well accepted boundaries under conditions of the German reimbursement system.